Van der Ende et al. (74) measured NPTX2 concentrations in the cerebrospinal fluid of 260 carriers with pathogenic mutations in GRN, C9orf72 or MAPT and some noncarrier individuals and found that NPTX2 might be a meaningful biomarker for the diagnosis of FTD. This evidence concerns the gene C9orf72 and frontotemporal dementia.